Dr. Falk Pharma

NCT00128739

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

NCT00180050

Budesonide Treatment for Lymphocytic Colitis

NCT00946946

Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine

NCT00180089

Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

NCT00300118

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

NCT00746447

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

NCT00449722

OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

NCT00450086

Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

NCT00747110

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

NCT00695643

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

NCT01278082

SOIBD Collagenous Colitis Maintenance Study

NCT00746486

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

NCT00887263

Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

NCT01086553

9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

NCT01038739

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01209208

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

NCT01208922

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

NCT01745770

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

NCT02142634

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

NCT02142725

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

NCT02280629

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

NCT02434029

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

NCT02493335

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

NCT03872921

norUrsodeoxycholic Acid vs Placebo in PSC

NCT06596252

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06886360

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)